Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6H9NO3 |
Molecular Weight | 143.1406 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(=O)OC(C)(C)C1=O
InChI
InChIKey=IRYJRGCIQBGHIV-UHFFFAOYSA-N
InChI=1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3
Molecular Formula | C6H9NO3 |
Molecular Weight | 143.1406 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Trimethadione (brand name is TRIDIONE) is an oxazolidinedione compound that was developed as an antiepileptic agent for control of petit mal seizures that are refractory to treatment with other drugs. Tridione does not modify the maximal seizure pattern in patients undergoing electroconvulsive therapy and has a sedative effect that may increase to the point of ataxia when excessive doses are used. Trimethadione acts as a voltage-activated T-type Ca2+ channel blocker. Trimethadione is rapidly absorbed from the gastrointestinal tract. It is demethylated by liver microsomes to the active metabolite, dimethadione. Approximately 3% of a daily dose of tridione is recovered in the urine as the unchanged drug. The majority of trimethadione is excreted slowly by the kidney in the form of dimethadione.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2362995 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16171802 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TRIDIONE Approved UseINDICATIONS TRIDIONE (trimethadione) is indicated for the control of petit mal seizures that are refractory to treatment with other drugs. Launch Date1946 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8441739/ |
4 mg/kg single, oral dose: 4 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
TRIMETHADIONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
148 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8441739/ |
4 mg/kg single, oral dose: 4 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
TRIMETHADIONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8441739/ |
4 mg/kg single, oral dose: 4 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
TRIMETHADIONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
150 mg 4 times / day multiple, oral Dose: 150 mg, 4 times / day Route: oral Route: multiple Dose: 150 mg, 4 times / day Co-administed with:: phenobarbital(15 mg. four times daily.) Sources: |
unhealthy, 16 years n = 1 Health Status: unhealthy Condition: petit mal seizures Age Group: 16 years Sex: M Population Size: 1 Sources: |
Disc. AE: Hepatitis... AEs leading to discontinuation/dose reduction: Hepatitis (1 patient) Sources: |
0.3 g 3 times / day multiple, oral (starting) Dose: 0.3 g, 3 times / day Route: oral Route: multiple Dose: 0.3 g, 3 times / day Co-administed with:: phénobarbital(4 grains (0.25 Gm.) daily) Sources: |
unhealthy, 23 years n = 1 Health Status: unhealthy Condition: petit mal seizures Age Group: 23 years Sex: F Population Size: 1 Sources: |
Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 5, 1 patient) Sources: |
0.3 g 3 times / day multiple, oral (starting) Dose: 0.3 g, 3 times / day Route: oral Route: multiple Dose: 0.3 g, 3 times / day Sources: |
unhealthy, 23 years n = 1 Health Status: unhealthy Condition: petit mal seizures Age Group: 23 years Sex: F Population Size: 1 Sources: |
Disc. AE: Agranulocytosis, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Agranulocytosis (grade 5, 1 patient) Sources: Thrombocytopenia (grade 5, 1 patient) |
24 g 1 times / day multiple, oral Studied dose Dose: 24 g, 1 times / day Route: oral Route: multiple Dose: 24 g, 1 times / day Sources: |
unhealthy n = 1 Health Status: unhealthy Condition: tetanus Sex: M Population Size: 1 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hepatitis | 1 patient Disc. AE |
150 mg 4 times / day multiple, oral Dose: 150 mg, 4 times / day Route: oral Route: multiple Dose: 150 mg, 4 times / day Co-administed with:: phenobarbital(15 mg. four times daily.) Sources: |
unhealthy, 16 years n = 1 Health Status: unhealthy Condition: petit mal seizures Age Group: 16 years Sex: M Population Size: 1 Sources: |
Aplastic anemia | grade 5, 1 patient Disc. AE |
0.3 g 3 times / day multiple, oral (starting) Dose: 0.3 g, 3 times / day Route: oral Route: multiple Dose: 0.3 g, 3 times / day Co-administed with:: phénobarbital(4 grains (0.25 Gm.) daily) Sources: |
unhealthy, 23 years n = 1 Health Status: unhealthy Condition: petit mal seizures Age Group: 23 years Sex: F Population Size: 1 Sources: |
Agranulocytosis | grade 5, 1 patient Disc. AE |
0.3 g 3 times / day multiple, oral (starting) Dose: 0.3 g, 3 times / day Route: oral Route: multiple Dose: 0.3 g, 3 times / day Sources: |
unhealthy, 23 years n = 1 Health Status: unhealthy Condition: petit mal seizures Age Group: 23 years Sex: F Population Size: 1 Sources: |
Thrombocytopenia | grade 5, 1 patient Disc. AE |
0.3 g 3 times / day multiple, oral (starting) Dose: 0.3 g, 3 times / day Route: oral Route: multiple Dose: 0.3 g, 3 times / day Sources: |
unhealthy, 23 years n = 1 Health Status: unhealthy Condition: petit mal seizures Age Group: 23 years Sex: F Population Size: 1 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
inconclusive | ||||
Page: 7.0 |
likely | |||
yes | ||||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Nephrotic syndrome caused by probenecid. | 1967 Jan 2 |
|
Di-n-propylacetic acid--profile of anticonvulsant activity in mice. | 1976 Feb |
|
Measurement of anticonvulsant activity in the Papio papio model of epilepsy. | 1976 Sep |
|
Anti-convulsant effect of phthalazino-2,3b-phthalazine-5(14H),12(7h)-dione (L-5418). I. Behavioral effect. | 1978 Feb |
|
Troxidone (trimethadione) embryopathy: case report with reveiw of the literature. | 1979 |
|
Comparison of the actions of trimethadione and chlordiazepoxide in animal models of anxiety and benzodiazepine receptor binding. | 1982 Nov |
|
Fetal anticonvulsant syndrome in rats: dose- and period-response relationships of prenatal diphenylhydantoin, trimethadione and phenobarbital exposure on the structural and functional development of the offspring. | 1983 Nov |
|
Anticonvulsive and convulsive effects of lidocaine: comparison with those of phenytoin, and implications for mechanism of action concepts. | 1988 Sep |
|
Dissolution of pancreatic stones by oral trimethadione in patients with chronic calcific pancreatitis. | 1994 Sep-Oct |
|
Anticonvulsants for soman-induced seizure activity. | 1999 Mar-Apr |
|
[Fetal trimethadione syndrome]. | 2001 |
|
Education and imaging. Hepatobiliary and pancreatic: oral therapy for pancreatic duct stones. | 2006 Sep |
|
Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. | 2007 Apr |
Patents
Sample Use Guides
Usual Adult Dosage: 0.9-2.4 grams daily in 3 or 4 equally divided doses (i.e., 300−600 mg 3 or 4 times daily). Initially, give 0.9 gram daily; increase this dose by 300 mg at weekly intervals until therapeutic results are seen or until toxic symptoms appear.
Children's Dosage: Usually 0.3-0.9 gram daily in 3 or 4 equally divided doses.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:07:51 GMT 2023
by
admin
on
Fri Dec 15 15:07:51 GMT 2023
|
Record UNII |
R7GV3H6FQ4
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000008486
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
||
|
WHO-ATC |
N03AC02
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
||
|
NDF-RT |
N0000175753
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
||
|
WHO-VATC |
QN03AC02
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
||
|
NCI_THESAURUS |
C264
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2751
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | |||
|
7316
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | |||
|
100000076924
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | |||
|
D014293
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | |||
|
5576
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | |||
|
TRIMETHADIONE
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | Description: Colourless, granular crystals; odour, slightly camphoraceous. Solubility: Soluble in water; freely soluble in ethanol (~750 g/l) TS and ether R. Category: Anticonvulsant. Storage: Trimethadione should be kept in a well-closed container. Definition: Trimethadione contains not less than 98.0% and not more than 101.0% of C6H9NO3, calculated with reference to the dried substance. | ||
|
1714
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | |||
|
SUB11307MIG
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | |||
|
127-48-0
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | |||
|
169503
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | |||
|
15799
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | |||
|
DTXSID9021396
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | |||
|
Trimethadione
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | |||
|
R7GV3H6FQ4
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | |||
|
10827
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | RxNorm | ||
|
204-845-8
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | |||
|
m11145
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB00347
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | |||
|
C47772
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY | |||
|
CHEMBL695
Created by
admin on Fri Dec 15 15:07:51 GMT 2023 , Edited by admin on Fri Dec 15 15:07:51 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
Metabolite to parent drug ratio in non-uraemic human plasma.
METABOLITE TO PARENT DRUG RATIO
PLASMA; URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
Dimethadione has anticonvulsant activity and has been used clinically in the treatment of petit mal epilepsy.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |